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Background: Here we present efficacy outcomes in ALK-
rearranged (ALK+) NSCLC patients with baseline (BL)
brain metastases (BM) treated with the selective oral
ALKi ceritinib in the ASCEND-1 (phase 1; NCT01283516)
and ASCEND-3 (phase 2; NCT01685138) trials.
Methods: ALKi-naive patients with ALK+ NSCLC and
stable BL BM received ceritinib 750 mg/day. Efficacy
analyses (by blinded independent review committee
[BIRC]) assessed whole body responses for ASCEND-1
and -3 according to RECIST 1.0 and 1.1 criteria, respec-
tively. Pooled intracranial responses were evaluated by
BIRC (ASCEND-1, retrospectively; ASCEND-3, prospec-
tively) in patients with measureable BL BM (RECIST 1.1).
Results: Of 26 and 50 ALKi-naïve patients with BL BM
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had prior brain radiotherapy (RT); median times from
prior RT to first ceritinib dose were 4.6 and 2.7 months.
Ceritinib showed whole body and intracranial efficacy
(Table). The most common AEs (ASCEND-1; ASCEND-3)
were nausea (84.6%; 78.0%), diarrhea (92.3%; 76.0%)
and vomiting (76.9%; 72.0%); 46 patients (ASCEND-1:
19; ASCEND-3: 27) had dose reductions and 4 patients
(ASCEND-1: 3; ASCEND-3: 1) discontinued due to AEs.
Conclusion: Clinically meaningful whole body and
intracranial activity with an acceptable tolerability
profile were observed in ALKi-naïve patients with
ALK+ NSCLC and BL BM treated with ceritinib.
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